4 results about "Biomarker discovery" patented technology

The present invention relates to an aptamer specifically binding to cell-derived extracellular vesicles and a method for discovering an extracellular vesicle-specific biomarker using same. Specifically, the present invention relates to an aptamer specifically binding to cancer cell-derived extracellular vesicles, and a method for discovering an extracellular vesicle-specific biomarker using same. Unlike prior art requiring immobilization, a method for selecting an aptamer specifically binding to extracellular vesicles according to the present invention can select an aptamer specifically binding to extracellular vesicles that maintain a three-dimensional structure in an actual clinical environment. A biomarker discovery method using the aptamer selected through the selection method can be used to quickly and precisely identify unknown target proteins present in extracellular vesicles. The present invention can be efficiently applied to the fields of novel biomarker discovery, target protein verification for diagnosis, and aptamer-protein interaction-based drug development.

The present invention provides a SPARK-seq high-throughput platform for the identification and kinetics analysis of nucleic acid aptamers and target proteins thereof. By combining cell screening, CRISPR gene perturbation and single-cell multi-omics sequencing technology, the platform enables systematic identification of the interaction between thousands of nucleic acid aptamers and target proteins thereof in a single experiment; in addition, high-throughput screening of high-stability nucleic acid aptamers having "slow dissociation" characteristics is achieved on the basis of dissociation kinetics. The method provided by the present invention overcomes the limitations of the traditional technology of low throughput, difficulty in identifying targets having relatively low abundance, and inability to perform efficiently screening in natural cell environments, not only achieves large-scale and unbiased discovery of aptamer targets, but also can accurately screen high-stability aptamers having slow dissociation rates, providing more powerful molecular tools and new biomarker discovery pathways for tumor diagnosis, targeted therapy, and accurate medical treatment.

This invention provides a SPARK-seq high-throughput platform for the identification and kinetic analysis of nucleic acid aptamers and their target proteins. This platform innovatively combines cell screening, CRISPR gene perturbation, and single-cell multi-omics sequencing technologies, enabling the systematic identification of thousands of nucleic acid aptamers and their target protein interactions in a single experiment. Simultaneously, it achieves, for the first time, high-throughput screening of highly stable nucleic acid aptamers with "slow dissociation" characteristics based on dissociation kinetics. The method provided by this invention overcomes the limitations of traditional techniques, such as low throughput, difficulty in identifying relatively low-abundance targets, and inability to perform efficient screening in natural cellular environments. It not only achieves large-scale, unbiased discovery of nucleic acid aptamer targets but also accurately screens for highly stable aptamers with slow dissociation rates, providing a more powerful molecular tool and a novel biomarker discovery pathway for tumor diagnosis, targeted therapy, and precision medicine.

This invention discloses a method for the simultaneous quantitative detection of multiple metabolites in biological samples. The method employs chromatographic tandem mass spectrometry (GC-MS) to detect the biological samples, comprising the following steps: (1) optimizing mass spectrometry detection parameters to obtain the optimal mass spectrometry detection parameters for each metabolite; (2) applying the optimal mass spectrometry detection parameters to detect the biological samples and classifying each metabolite; (3) optimizing and obtaining the final CE value for each metabolite; (4) using the final CE value corresponding to each metabolite to detect the biological sample to be tested, and using the internal standard method to perform quantitative analysis of each metabolite in the biological sample to be tested, thereby obtaining the content of each metabolite in the biological sample to be tested. Furthermore, an absolute quantitative analysis method based on eliminating interference from natural isotopes in metabolites is also provided. The method of this invention has high throughput, high accuracy, simple operation, high experimental reproducibility and operability, and can be applied to clinical pathophysiological research and biomarker discovery.